For the roughly 300 million people living with asthma worldwide, the condition has long been understood as a pulmonary burden — but mounting evidence suggests it may simultaneously be reshaping the brain. A comprehensive review in the Journal of Neuroinflammation reframes asthma as a systemic inflammatory syndrome with meaningful neurological consequences, challenging the assumption that airway disease stays confined to the lungs.
The review maps several convergent biological pathways through which asthma may sustain neuroinflammation. Chronic pulmonary inflammation generates systemic cytokine spillover capable of breaching the blood-brain barrier, seeding central inflammatory cascades. Simultaneously, oxidative stress and mitochondrial dysfunction compound neuronal vulnerability, while gut-lung-brain microbial crosstalk — increasingly recognized as a bidirectional regulatory network — may amplify glial activation. Sleep fragmentation, common in poorly controlled asthma, adds another neuroinflammatory driver. Biomarker data strengthen the case: elevated plasma glial fibrillary acidic protein (GFAP) and neurofilament light chains (NfL) have been detected in severe asthma patients, alongside altered hippocampal metabolism and white matter abnormalities on neuroimaging — signatures overlapping with early neurodegenerative disease. Epidemiological cohorts link asthma to increased all-cause dementia and Alzheimer's disease risk, though effect sizes and consistency vary across studies.
This review arrives at a genuinely important intersection in chronic disease research. The lung-brain axis framework it elaborates is biologically coherent and aligns with the broader recognition that systemic inflammation is a transdiagnostic driver of neurodegeneration. However, the evidence base carries important limitations: most epidemiological associations are observational and susceptible to confounding by corticosteroid exposure, sleep disorders, and shared metabolic risk factors. Causal directionality remains unresolved — neuroinflammation may partly precede or worsen asthma control rather than purely result from it. The Parkinson's disease connection acknowledged as more preliminary reflects the field's early stage. This is an incremental but well-synthesized contribution that should prompt longitudinal prospective studies tracking neurological biomarkers across asthma severity strata.